BR112022016894A2 - Anticorpos novos - Google Patents

Anticorpos novos

Info

Publication number
BR112022016894A2
BR112022016894A2 BR112022016894A BR112022016894A BR112022016894A2 BR 112022016894 A2 BR112022016894 A2 BR 112022016894A2 BR 112022016894 A BR112022016894 A BR 112022016894A BR 112022016894 A BR112022016894 A BR 112022016894A BR 112022016894 A2 BR112022016894 A2 BR 112022016894A2
Authority
BR
Brazil
Prior art keywords
antibodies
new antibodies
tcr
gamma
methods
Prior art date
Application number
BR112022016894A
Other languages
English (en)
Portuguese (pt)
Inventor
Polyakova Oxana
Nussbaumer Oliver
Hayday Adrian
Vantourout Pierre
Original Assignee
Gammadelta Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gammadelta Therapeutics Ltd filed Critical Gammadelta Therapeutics Ltd
Publication of BR112022016894A2 publication Critical patent/BR112022016894A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112022016894A 2020-02-24 2021-02-24 Anticorpos novos BR112022016894A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2002581.3A GB202002581D0 (en) 2020-02-24 2020-02-24 Novel antibodies
PCT/GB2021/050459 WO2021171002A1 (en) 2020-02-24 2021-02-24 Novel antibodies

Publications (1)

Publication Number Publication Date
BR112022016894A2 true BR112022016894A2 (pt) 2023-04-04

Family

ID=70108379

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022016894A BR112022016894A2 (pt) 2020-02-24 2021-02-24 Anticorpos novos
BR112022016671A BR112022016671A2 (pt) 2020-02-24 2021-02-24 Método ex vivo de modulação de células t gama variável 4, população de células t vy4, composição, composição farmacêutica, e, método de tratamento de um câncer, uma doença infecciosa ou uma doença inflamatória em um sujeito em necessidade

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022016671A BR112022016671A2 (pt) 2020-02-24 2021-02-24 Método ex vivo de modulação de células t gama variável 4, população de células t vy4, composição, composição farmacêutica, e, método de tratamento de um câncer, uma doença infecciosa ou uma doença inflamatória em um sujeito em necessidade

Country Status (17)

Country Link
US (2) US20230090901A1 (https=)
EP (3) EP4110387B1 (https=)
JP (2) JP2023516925A (https=)
KR (2) KR20220164473A (https=)
CN (2) CN115697401A (https=)
AU (2) AU2021228266A1 (https=)
BR (2) BR112022016894A2 (https=)
CA (2) CA3168973A1 (https=)
CL (1) CL2022002296A1 (https=)
CO (2) CO2022013542A2 (https=)
EC (1) ECSP22074030A (https=)
GB (1) GB202002581D0 (https=)
IL (2) IL295696A (https=)
MX (2) MX2022010239A (https=)
PE (1) PE20230438A1 (https=)
WO (2) WO2021171003A1 (https=)
ZA (1) ZA202209699B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202006989D0 (en) * 2020-05-12 2020-06-24 Gammadelta Therapeutics Ltd Methods for isolating gamma delta t cells
MX2023009544A (es) 2021-02-17 2023-11-28 Gammadelta Therapeutics Ltd Anticuerpos anti-variable delta 1 de tcr multiespecíficos.
CN119080924B (zh) * 2024-07-04 2025-02-25 上海交通大学医学院附属第九人民医院 一种单克隆免疫球蛋白及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297773B2 (en) * 2014-11-17 2024-07-01 Adicet Bio Inc Engineered gamma delta t-cells
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
US11299708B2 (en) * 2016-05-12 2022-04-12 Adicet Bio, Inc. Methods for selective expansion of γδ T-cell populations and compositions thereof
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
JP2022545196A (ja) * 2019-08-16 2022-10-26 ガンマデルタ セラピューティクス リミテッド 抗ｔｃｒデルタ可変１抗体の治療的使用

Also Published As

Publication number Publication date
US20230090901A1 (en) 2023-03-23
EP4591882A2 (en) 2025-07-30
AU2021228266A1 (en) 2022-10-13
PE20230438A1 (es) 2023-03-08
WO2021171002A1 (en) 2021-09-02
CA3172340A1 (en) 2021-09-02
CA3168973A1 (en) 2021-09-02
ZA202209699B (en) 2024-12-18
EP4110387A1 (en) 2023-01-04
ECSP22074030A (es) 2022-10-31
KR20220164473A (ko) 2022-12-13
EP4110387B1 (en) 2025-05-21
GB202002581D0 (en) 2020-04-08
KR20220145894A (ko) 2022-10-31
CO2022013633A2 (es) 2023-02-16
BR112022016671A2 (pt) 2022-11-16
CN115697401A (zh) 2023-02-03
CN115461369A (zh) 2022-12-09
IL295852A (en) 2022-10-01
JP2023514437A (ja) 2023-04-05
US20230159638A1 (en) 2023-05-25
MX2022010239A (es) 2022-11-14
EP4110813A1 (en) 2023-01-04
CL2022002296A1 (es) 2023-03-31
JP2023516925A (ja) 2023-04-21
AU2021225390A1 (en) 2022-09-22
EP4591882A3 (en) 2025-10-15
IL295696A (en) 2022-10-01
CO2022013542A2 (es) 2022-10-11
MX2022010383A (es) 2022-09-05
WO2021171003A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
BR112022016894A2 (pt) Anticorpos novos
BR112022012524A2 (pt) Porção química de ligação que se liga especificamente a claudin18.2, polinucleotídeo, vetor, célula hospedeira, receptor de antígeno quimérico (car ), célula imune geneticamente modificada, composição farmacêutica, método de tratamento de um tumor ou câncer que expressa claudin18.2
BR112022013545A2 (pt) Anticorpos anti-tigit e método de uso
ECSP20039728A (es) Anticuerpos monoclonales y métodos para utilizar los mismos
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
PE20220217A1 (es) Anticuerpos humanizados contra la region de la cadena beta de la 9na familia trbv9 del tcr humano, y sus metodos de uso
BR112022015450A2 (pt) Anticorpo monoclonal isolado ou fragmento de conexão ao antígeno dele, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, proteína do receptor de antígeno quimérico (car), célula modificada, método para tratar ou melhorar o efeito de um câncer em um sujeito, método para potencializar a ativação de células t em um sujeito e método para modular o fenótipo de macrófagos m2a em um sujeito
BR112022019129A2 (pt) Anticorpos de ligação a siglec15 e usos dos mesmos
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
CY1116031T1 (el) Aνti-ilt7 αντισωμα
CL2021001704A1 (es) Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso.
BR112022020256A2 (pt) “anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
BR112021016435A2 (pt) Receptores de antígenos quiméricos responsivos à hipóxia
BR112021026309A2 (pt) Anticorpos para ativação de células t
MX2022002672A (es) Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
BR112023003366A2 (pt) Moléculas multiespecíficas de ligação ao antígeno que têm como alvo hiv e métodos de uso
BR112022016232A2 (pt) Proteínas biespecíficas anti-her2 manipuladas
BR112021021281A2 (pt) Anticorpo monoclonal que se liga especificamente ao gitr
PE20231552A1 (es) Anticuerpos biespecificos para linfocitos t activados por proteasa
Bu et al. Monitoring PD-1 phosphorylation to evaluate PD-1 signaling during antitumor immune responses
BR112022000755A2 (pt) Combinação, composição farmacêutica, kit para uso no tratamento de câncer, uso, método para o tratamento de câncer, e, teste diagnóstico para determinar se um paciente se beneficiará do tratamento
BR112022021065A2 (pt) Anticorpos terapêuticos de musk
MX2023003304A (es) Complejo de union de egfr y metodo de fabricacion y uso del mismo.
Khedri et al. Development and evaluation of novel aptamers specific for human PD1 using hybrid systematic evolution of ligands by exponential enrichment approach